Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Isleworth Healthcare Acquisition Corp. (ISLE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
10.00+0.01 (+0.10%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.99
Open10.00
Bid9.98 x 1400
Ask10.02 x 800
Day's Range9.99 - 10.00
52 Week Range9.66 - 10.00
Volume114,572
Avg. Volume66,546
Market Cap261.912M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journals

    St. Pete SPAC calls off merger agreement

    A St. Petersburg-based special purpose acquisition company is terminating a merger agreement two months after inking the deal. Isleworth Healthcare Acquisition Corp. (Nasdaq: ISLE) and Aventura-based Cytovia Holdings Inc. agreed to the mutual termination agreement on June 30 after both companies’ boards of directors determined the merger would not be in stockholders’ best interests, according to documents filed with the U.S. Securities and Exchange Commission. SPAC mergers have been upended by market turmoil, with at least four deals falling through within a 24-hour period at the start of the month as the S&P 500 slipped into bear market territory for the first time since March 2020, according to Bloomberg SPAC Research.

  • Benzinga

    Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut

    About 14 months after inking a natural killer cell deal with Cellectis SA (NASDAQ: CLLS), Cytovia plans to list on NASDAQ via a merger with the SPAC Isleworth Healthcare Acquisition Corp (NASDAQ: ISLE). The company went on to create a China joint venture. The biotech teamed up with China-based biotech investor TF Capital to form CytoLynx Therapeutics with $45 million in funding in September 2021. Related: Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China. The blank-

  • Simply Wall St.

    Is Isleworth Healthcare Acquisition Corp. (NASDAQ:ISLE) Popular Amongst Institutions?

    A look at the shareholders of Isleworth Healthcare Acquisition Corp. ( NASDAQ:ISLE ) can tell us which group is most...

Advertisement
Advertisement